Emapalumab Efficacy in Children With Primary Hemophagocytic Lymphohistiocytosis
NCT06587191 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 7
Last updated 2024-10-01
Summary
The goal of this retrospective study is to assess efficacy and safety of emapalumab prescribed for the treatment in children with refractory from of pHLH.
Conditions
- Primary Hemophagocytic Lymphohistiocytosis
Sponsors & Collaborators
-
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
lead OTHER
Principal Investigators
-
Anna Scherbina, MD,Phd · Chief HSCT department at Federal Research Center for pediatric hematology, oncology and immunology
Eligibility
- Min Age
- 1 Day
- Max Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2024-08-01
- Primary Completion
- 2024-09-01
- Completion
- 2024-10-01
Countries
- Russia
Study Locations
More Related Trials
-
Phase I Study of Ipilimumab (Anti-CTLA-4) in Children and Adolescents With Treatment-Resistant Cancer
NCT01445379 ·Status: COMPLETED ·Phase: PHASE1
-
Phase II Study of Everolimus in Children and Adolescents With Refractory or Relapsed Rhabdomyosarcoma and Other Soft Tissue Sarcomas
NCT01216839 ·Status: UNKNOWN ·Phase: PHASE2
-
Treatment of Leukemia and Lymphoma in Children With Ataxia Telangiectasia
NCT04037189 ·Status: UNKNOWN
-
Pucotenlimab Combined With Lenvatinib and Chemotherapy in the Treatment of Advanced, Relapsed/Refractory Hepatoblastoma in Children
NCT07188311 ·Status: RECRUITING ·Phase: NA
-
Multi-centre Prospective Cohort of Childhood Leukaemia: Determinants of Health and Quality of Life of the Patients After Treatment for an Acute Leukaemia During Childhood or Adolescence - LEA
NCT01756599 ·Status: UNKNOWN ·Phase: NA
-
A Multi-institutional Study for Treatment of Children With Newly Diagnosed Hepatoblastoma Using a Modified PHITT Strategy
NCT04478292 ·Status: RECRUITING ·Phase: PHASE3
-
A Combined Study in Pediatric Cancer Patients for Dose Ranging and Efficacy/Safety of Plerixafor Plus Standard Regimens for Mobilization Versus Standard Regimens Alone
NCT01288573 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Panitumumab in Children With Solid Tumors
NCT00658658 ·Status: COMPLETED ·Phase: PHASE1
-
Sorafenib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia
NCT01445080 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Clinical Trial of GAIA-102 for Refractory/Relapse Neuroblastomas and Other Malignant Pediatric Solid Tumors
NCT05608148 ·Status: RECRUITING ·Phase: PHASE1
-
Stem Cell Harvesting Using GCSF Plus Plerxiafor, in First -Line, for Heavily Pre- Treated Pediatric Oncology Patients.
NCT02006225 ·Status: UNKNOWN ·Phase: PHASE4
-
Study of Dalotuzumab Alone and With Ridaforolimus in Pediatric Participants With Advanced Solid Tumors (MK-8669-062 AM1)
NCT01431547 ·Status: COMPLETED ·Phase: PHASE1
-
A Multi-Institution Study of TGFβ Imprinted, Ex Vivo Expanded Universal Donor NK Cell Infusions as Adoptive Immunotherapy in Combination With Gemcitabine and Docetaxel in Patients With Relapsed or Refractory Pediatric Bone and Soft Tissue
NCT05634369 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Lymphoproliferative Disorders After Diagnosis of Childhood Acute Lymphoblastic Leukemia/Lymphoma
NCT04055558 ·Status: UNKNOWN
-
Immunotherapy for Solid Tumor Malignancies in Pediatrics Using Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor T Cells
NCT07148050 ·Status: RECRUITING ·Phase: PHASE1
-
A Study of Lenvatinib (MK-7902) in Pediatric Participants With Relapsed or Refractory Solid Malignancies (MK-7902-013/E7080)
NCT04447755 ·Status: COMPLETED ·Phase: PHASE2
-
A Compassionate Use/Expanded Access Protocol Using 131I-MIBG Therapy for Patients With Refractory Neuroblastoma and Metastatic Pheochromocytoma
NCT03015844 ·Status: AVAILABLE
-
Clinical Study of Eflornithine After Immunotherapy for High-risk Neuroblastoma（CSHEIN）
NCT07278674 ·Status: ACTIVE_NOT_RECRUITING
-
Pilot Study of Redirected Haploidentical Natural Killer Cell Infusions for B-Lineage Acute Lymphoblastic Leukemia
NCT01974479 ·Status: SUSPENDED ·Phase: PHASE1
-
A Study of Safety, Tolerability, and Pk of rhMBL in Pediatric Hematology/Oncology Pts With Fever and Neutropenia
NCT00520325 ·Status: WITHDRAWN ·Phase: PHASE1
-
Treatment of Newly Diagnosed High Risk Pediatric Acute Lymphoblastic Leukemia
NCT06184009 ·Status: RECRUITING ·Phase: PHASE2
-
A Pilot Study of Tumor-Specific Peptide Vaccination and IL-2 With or Without Autologous T Cell Transplantation in Recurrent Pediatric Sarcomas
NCT00001564 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Evaluate Tovorafenib in Pediatric and Young Adult Participants With Relapsed or Progressive Low-Grade Glioma and Advance Solid Tumors
NCT04775485 ·Status: RECRUITING ·Phase: PHASE2
-
SPEARHEAD-3 Pediatric Study
NCT05642455 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Phase I Clinical Trial of Anlotinib in Progressive, Recurrent, and Refractory Sarcoma in Children
NCT04659733 ·Status: UNKNOWN ·Phase: PHASE1